Detalles de la búsqueda
1.
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
BMC Infect Dis
; 21(1): 222, 2021 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637050
2.
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Eur J Haematol
; 104(4): 352-355, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31922303
3.
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Support Care Cancer
; 28(2): 857-866, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31161436
4.
Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
BMC Infect Dis
; 21(1): 340, 2021 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33845777
5.
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
J Comp Eff Res
; 12(8): e230004, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431849
6.
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
J Med Econ
; 26(1): 1108-1121, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632452
7.
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.
Blood Adv
; 7(5): 832-844, 2023 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973195
8.
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Oncol Res Treat
; 44(12): 672-681, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34749378
9.
Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland.
Leuk Res
; 91: 106334, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32135394
10.
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Int J Immunopathol Pharmacol
; 34: 2058738420980258, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33353443
11.
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.
Cancers (Basel)
; 12(4)2020 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32340174
12.
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Cancer Med
; 9(16): 5819-5826, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32608149
13.
[Important developments in the therapy of AML]. / Die wichtigsten Neuerungen bei akuter myeloischer Leukämie.
MMW Fortschr Med
; 165(1): 36-39, 2023 01.
Artículo
en Alemán
| MEDLINE | ID: mdl-36648670
Resultados
1 -
13
de 13
1
Próxima >
>>